<!DOCTYPE html><html lang="en" class="server-only"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/><title>A New Era in Radiopharmaceutical Development, Supply Chain, and Manufacturing: Introducing Nucleus Radiopharma - Eclipse</title><link rel="canonical" href="index.html"/><meta property="og:locale" content="en_US"/><meta property="og:type" content="article"/><meta property="og:title" content="A New Era in Radiopharmaceutical Development, Supply Chain, and Manufacturing: Introducing Nucleus Radiopharma - Eclipse"/><meta property="og:description" content="The Eclipse team is excited to announce the creation and funding of Nucleus Radiopharma in partnership with Mayo Clinic"/><meta property="og:url" content="https://eclipse.vc/blog/a-new-era-in-radiopharmaceutical-development-supply-chain-and-manufacturing-introducing-nucleus-radiopharma/"/><meta property="og:site_name" content="Eclipse"/><meta property="article:published_time" content="2022-10-12T15:58:04+00:00"/><meta property="article:modified_time" content="2022-11-03T19:48:39+00:00"/><meta property="og:image" content="https://eclipsevcprod.wpengine.com/wp-content/uploads/2022/10/Nucleus-Announcement-1.jpg"/><meta property="og:image:width" content="1280"/><meta property="og:image:height" content="876"/><meta property="og:image:type" content="image/jpeg"/><meta name="author" content="Justin Butler"/><meta name="twitter:card" content="summary_large_image"/><meta name="twitter:creator" content="@eclipseventures"/><meta name="twitter:site" content="@eclipseventures"/><meta name="twitter:label1" content="Written by"/><meta name="twitter:data1" content="Justin Butler"/><meta name="twitter:label2" content="Est. reading time"/><meta name="twitter:data2" content="3 minutes"/><script type="application/ld+json" class="yoast-schema-graph">{"@context":"https://schema.org","@graph":[{"@type":"WebPage","@id":"https://eclipse.vc/blog/a-new-era-in-radiopharmaceutical-development-supply-chain-and-manufacturing-introducing-nucleus-radiopharma/","url":"https://eclipse.vc/blog/a-new-era-in-radiopharmaceutical-development-supply-chain-and-manufacturing-introducing-nucleus-radiopharma/","name":"A New Era in Radiopharmaceutical Development, Supply Chain, and Manufacturing: Introducing Nucleus Radiopharma - Eclipse","isPartOf":{"@id":"https://eclipsevcprod.wpengine.com/#website"},"primaryImageOfPage":{"@id":"https://eclipse.vc/blog/a-new-era-in-radiopharmaceutical-development-supply-chain-and-manufacturing-introducing-nucleus-radiopharma/#primaryimage"},"image":{"@id":"https://eclipse.vc/blog/a-new-era-in-radiopharmaceutical-development-supply-chain-and-manufacturing-introducing-nucleus-radiopharma/#primaryimage"},"thumbnailUrl":"https://i0.wp.com/eclipsevcprod.wpengine.com/wp-content/uploads/2022/10/Nucleus-Announcement-1.jpg?fit=1280%2C876&ssl=1","datePublished":"2022-10-12T15:58:04+00:00","dateModified":"2022-11-03T19:48:39+00:00","author":{"@id":"https://eclipsevcprod.wpengine.com/#/schema/person/a11b6fbff0284496e1bbe2056e0bf6d5"},"breadcrumb":{"@id":"https://eclipse.vc/blog/a-new-era-in-radiopharmaceutical-development-supply-chain-and-manufacturing-introducing-nucleus-radiopharma/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https://eclipse.vc/blog/a-new-era-in-radiopharmaceutical-development-supply-chain-and-manufacturing-introducing-nucleus-radiopharma/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https://eclipse.vc/blog/a-new-era-in-radiopharmaceutical-development-supply-chain-and-manufacturing-introducing-nucleus-radiopharma/#primaryimage","url":"https://i0.wp.com/eclipsevcprod.wpengine.com/wp-content/uploads/2022/10/Nucleus-Announcement-1.jpg?fit=1280%2C876&ssl=1","contentUrl":"https://i0.wp.com/eclipsevcprod.wpengine.com/wp-content/uploads/2022/10/Nucleus-Announcement-1.jpg?fit=1280%2C876&ssl=1","width":1280,"height":876},{"@type":"BreadcrumbList","@id":"https://eclipse.vc/blog/a-new-era-in-radiopharmaceutical-development-supply-chain-and-manufacturing-introducing-nucleus-radiopharma/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://eclipse.vc/"},{"@type":"ListItem","position":2,"name":"A New Era in Radiopharmaceutical Development, Supply Chain, and Manufacturing: Introducing Nucleus Radiopharma"}]},{"@type":"WebSite","@id":"https://eclipsevcprod.wpengine.com/#website","url":"https://eclipsevcprod.wpengine.com/","name":"Eclipse","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https://eclipsevcprod.wpengine.com/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https://eclipsevcprod.wpengine.com/#/schema/person/a11b6fbff0284496e1bbe2056e0bf6d5","name":"Justin Butler","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https://eclipsevcprod.wpengine.com/#/schema/person/image/","url":"https://secure.gravatar.com/avatar/7bd4dbca88ac7a9e2a5851061b2630fa?s=96&d=mm&r=g","contentUrl":"https://secure.gravatar.com/avatar/7bd4dbca88ac7a9e2a5851061b2630fa?s=96&d=mm&r=g","caption":"Justin Butler"},"url":"https://eclipsevcprod.wpengine.com/blog/author/justin-butler/"}]}</script><meta name="theme-color" content="#ffffff"/><meta name="msapplication-TileColor" content="#ffffff"/><link rel="apple-touch-icon" sizes="180x180" href="../../favicons/apple-touch-icon.png"/><link rel="icon" type="image/png" sizes="32x32" href="../../favicons/favicon-32x32.png"/><link rel="icon" type="image/png" sizes="16x16" href="../../favicons/favicon-16x16.png"/><link rel="manifest" href="../../favicons/site.webmanifest" crossorigin="use-credentials"/><link rel="mask-icon" href="../../favicons/safari-pinned-tab.svg" color="#000000"/><link rel="shortcut icon" href="../../favicons/favicon.ico"/><meta name="msapplication-config" content="/favicons/browserconfig.xml"/><meta name="next-head-count" content="34"/><link rel="preload" href="../../_next/static/css/2a1ae64787bca2b8.css" as="style"/><link rel="stylesheet" href="../../_next/static/css/2a1ae64787bca2b8.css" data-n-g=""/><link rel="preload" href="../../_next/static/css/9e48c417edf57fbb.css" as="style"/><link rel="stylesheet" href="../../_next/static/css/9e48c417edf57fbb.css" data-n-p=""/><link rel="preload" href="../../_next/static/css/99307392305fa1c6.css" as="style"/><link rel="stylesheet" href="../../_next/static/css/99307392305fa1c6.css" data-n-p=""/><noscript data-n-css=""></noscript><script defer="" nomodule="" src="../../_next/static/chunks/polyfills-c67a75d1b6f99dc8.js"></script><script src="../../_next/static/chunks/webpack-a083670f4f93d229.js" defer=""></script><script src="../../_next/static/chunks/framework-1b1477f9717fa649.js" defer=""></script><script src="../../_next/static/chunks/main-9df23afce8a37256.js" defer=""></script><script src="../../_next/static/chunks/pages/_app-b6f47eef7b5d62d4.js" defer=""></script><script src="../../_next/static/chunks/421-ab3a214a05e31e83.js" defer=""></script><script src="../../_next/static/chunks/253-9d1b7d0fde0d5c89.js" defer=""></script><script src="../../_next/static/chunks/194-da48473659fed9ed.js" defer=""></script><script src="../../_next/static/chunks/pages/blog/[postSlug]-d13980b33090540f.js" defer=""></script><script src="../../_next/static/PXZ38zmr2SXTuXgWIih-y/_buildManifest.js" defer=""></script><script src="../../_next/static/PXZ38zmr2SXTuXgWIih-y/_ssgManifest.js" defer=""></script></head><script data-cfasync="false">
  if (typeof window !== 'undefined') document.documentElement.classList.add('hide-static-html');
</script><body><noscript id="gtm-noscript"><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-KVCPZSV" height="0" width="0"></iframe></noscript><div id="__next" data-reactroot=""><nav class="Nav_Nav__51Y57"><div class="Nav_overlay__WPxUz"></div><div class="Nav_wrapper__Ov3uU"><div class="Nav_logoCon__xUfYU"><a aria-label="logo-link" href="../../index.html"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 112 70" class="Nav_logo__b6zpd"><path fill="currentColor" d="M37.17 29.26v11.21h7.76v-2.53h-4.77v-8.68h-2.99zm35.24 0h-4.53v11.21h3v-3.22h1.54c2.85 0 4.43-1.68 4.43-4 0-2.32-1.59-3.99-4.44-3.99zm-.15 5.49h-1.39V31.8h1.39a1.48 1.48 0 110 2.95zm19.04-1.06l-1.49-.49c-.54-.18-.79-.4-.79-.83 0-.43.37-.77 1.09-.77a2.52 2.52 0 011.94.81l1.72-1.8A4.79 4.79 0 0090 29.13c-2 0-3.83 1.13-3.83 3.34 0 1.85 1.16 2.84 2.79 3.38l1.32.45c.74.24 1.1.47 1.1 1 0 .63-.53.89-1.42.89a2.83 2.83 0 01-2.34-1.22l-2.22 1.58a5.52 5.52 0 004.6 2.08c3 0 4.26-1.48 4.26-3.54.04-1.58-.72-2.66-2.96-3.4zm20.7-1.91v-2.52h-8.09v11.21H112v-2.53h-5.09v-1.92h4.05v-2.39h-4.05v-1.85H112zM0 40.47h8.09v-2.53H3v-1.92h4.05v-2.39H3v-1.85h5.09v-2.52H0v11.21zm27.48-2.28l-2.19-1.55a3.08 3.08 0 110-3.54l2.19-1.55a5.75 5.75 0 100 6.64zm26.1-11.93h3A34.88 34.88 0 0022.76 0h-1.49a34.89 34.89 0 0132.31 26.26zm.62 3c.298 1.852.448 3.724.45 5.6a35.792 35.792 0 01-.45 5.61h3c.6-3.713.6-7.498 0-11.21h-3zM21.27 69.69h1.49a34.88 34.88 0 0033.79-26.23h-3a34.86 34.86 0 01-32.28 26.23z"></path></svg></a></div><ul class="Nav_routes__RvPpl"><li class="Nav_isDropdown__T7dCf"><div class="Nav_hasChildren__Bx5Kf"><div class="Nav_overlay__WPxUz"></div><button>Our Perspective<span class="Nav_circle__xqUJc"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 25 25" class="Nav_svg__iQzTA"><path stroke="currentColor" stroke-linecap="square" d="M19 11l-6.5 6L6 11"></path></svg></span></button><div class="Nav_childrenItems__ox0Jb"><a aria-label="Mission-menu" class="" href="../../venture-equity/index.html">Mission<svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 25 25" class="Nav_svg__iQzTA"><path stroke="currentColor" stroke-linecap="square" d="M19 11l-6.5 6L6 11"></path></svg></a><a aria-label="ECO Report-menu" class="" href="https://ecoreport.eclipse.vc">ECO Report<svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 25 25" class="Nav_svg__iQzTA"><path stroke="currentColor" stroke-linecap="square" d="M19 11l-6.5 6L6 11"></path></svg></a></div></div></li><li class=""><a aria-label="Our Team-menu" href="../../team/index.html">Our Team<span class="Nav_bottomLine__KJZ_W"></span></a></li><li class=""><a aria-label="Our Companies-menu" href="../../portfolio/index.html">Our Companies<span class="Nav_bottomLine__KJZ_W"></span></a></li><li class="Nav_isDropdown__T7dCf Nav_activeRoute__irBxx"><div class="Nav_hasChildren__Bx5Kf"><div class="Nav_overlay__WPxUz"></div><button>News &amp; Insights<span class="Nav_circle__xqUJc"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 25 25" class="Nav_svg__iQzTA"><path stroke="currentColor" stroke-linecap="square" d="M19 11l-6.5 6L6 11"></path></svg></span></button><div class="Nav_childrenItems__ox0Jb"><a aria-label="Blog-menu" class="Nav_activeRoute__irBxx" href="../index.html">Blog<svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 25 25" class="Nav_svg__iQzTA"><path stroke="currentColor" stroke-linecap="square" d="M19 11l-6.5 6L6 11"></path></svg></a><a aria-label="Recent Press-menu" class="" href="../../press/index.html">Recent Press<svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 25 25" class="Nav_svg__iQzTA"><path stroke="currentColor" stroke-linecap="square" d="M19 11l-6.5 6L6 11"></path></svg></a></div></div></li></ul></div></nav><main class="PostComponent_PostComponent__2sBnR"><section class="blog-hero"><div class="BlogHero_BlogHero__WYSP0"><div class="BlogHero_wrapper__zm6cS"><figure class="Image_Image__gOsxL BlogHero_image__A7p8M"><img class="" src="https://i0.wp.com/eclipsevcprod.wpengine.com/wp-content/uploads/2022/10/Nucleus-Announcement-1.jpg?fit=1280%2C876&amp;ssl=1" srcSet="https://i0.wp.com/eclipsevcprod.wpengine.com/wp-content/uploads/2022/10/Nucleus-Announcement-1.jpg?fit=1280%2C876&amp;ssl=1&amp;w=640&amp;quality=90 320w, https://i0.wp.com/eclipsevcprod.wpengine.com/wp-content/uploads/2022/10/Nucleus-Announcement-1.jpg?fit=1280%2C876&amp;ssl=1&amp;w=960&amp;quality=90 480w, https://i0.wp.com/eclipsevcprod.wpengine.com/wp-content/uploads/2022/10/Nucleus-Announcement-1.jpg?fit=1280%2C876&amp;ssl=1&amp;w=1280&amp;quality=90 640w, https://i0.wp.com/eclipsevcprod.wpengine.com/wp-content/uploads/2022/10/Nucleus-Announcement-1.jpg?fit=1280%2C876&amp;ssl=1&amp;w=1600&amp;quality=90 800w" alt="" decoding="async" loading="lazy"/></figure><h2 class="BlogHero_title__zLtPC">A New Era in Radiopharmaceutical Development, Supply Chain, and Manufacturing: Introducing Nucleus Radiopharma</h2><div class="BlogHero_data__oHW8v"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 14 15"><path fill="currentColor" d="M13.607 3.186l-1.795-1.795a1.331 1.331 0 00-.948-.393c-.358 0-.695.14-.948.393L.944 10.363a.367.367 0 00-.098.175l-.823 3.455a.81.81 0 00.216.766.81.81 0 00.766.216l3.455-.823a.368.368 0 00.175-.098l8.972-8.972c.254-.253.393-.59.393-.948s-.14-.695-.393-.948zM4.188 13.46l-3.353.799a.076.076 0 01-.074-.021.075.075 0 01-.02-.074l.798-3.354 7.007-7.006 2.649 2.65-7.006 7.006zm8.9-8.9l-1.372 1.372-2.65-2.649 1.372-1.371a.6.6 0 01.853 0l1.796 1.796a.599.599 0 01.177.426.599.599 0 01-.177.427z"></path></svg><p>Justin Butler</p><span class="BlogHero_divider__jOHYB">|</span><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 25 25"><path stroke="currentColor" stroke-width="2" d="M3.08 3.1h18.83v19.26H3.08z"></path><path stroke="currentColor" stroke-linejoin="round" stroke-width="2" d="M7.293 1.042v4.252M17.71 1.042v4.252"></path><path stroke="currentColor" stroke-width="2" d="M2.083 10.608h19.793"></path></svg><p>Oct 12, 2022</p><span class="BlogHero_divider__jOHYB">|</span><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 25 25"><g stroke="currentColor" stroke-linecap="round" stroke-linejoin="round" stroke-width="2" clip-path="url(#clock_svg__clock_svg__clip0_910_8361)"><path d="M21.917 12.5c0 5.2-4.216 9.416-9.417 9.416a9.417 9.417 0 119.417-9.417z"></path><path d="M11.5 8.291v4.86l3.166 2.515"></path></g><defs><clipPath id="clock_svg__clock_svg__clip0_910_8361"><path fill="#fff" d="M0 0h20.83v20.83H0z" transform="translate(2.083 2.083)"></path></clipPath></defs></svg><p>2<!-- --> MIN</p></div><p class="BlogHero_excerpt___pf74">The Eclipse team is excited to announce the creation and funding of Nucleus Radiopharma in partnership with Mayo Clinic
</p><div class="SocialShare_SocialShare___TeOc"><p class="SocialShare_text___6CJT">Share</p><span class="SocialShare_separator___IJQy"></span><a aria-label="" target="_blank" rel="no-referrer" href="https://eclipse.vc/blog/[postSlug]/"><span class="ThemedButton ThemedButton_ThemedButton__Hdkso SocialShare_button__SJnz4 ThemedButton_icon__OZyeS">Twitter<svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 9 9" class="ThemedButton_svg__7_dpk"><path stroke="currentColor" stroke-linecap="square" stroke-width="0.67" d="M.912 1.088l7.028.043m0 0l.043 7.028M7.94 1.131L.869 8.203"></path></svg></span></a><a aria-label="" target="_blank" rel="no-referrer" href="https://eclipse.vc/blog/[postSlug]/"><span class="ThemedButton ThemedButton_ThemedButton__Hdkso SocialShare_button__SJnz4 ThemedButton_icon__OZyeS">Linkedin<svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 9 9" class="ThemedButton_svg__7_dpk"><path stroke="currentColor" stroke-linecap="square" stroke-width="0.67" d="M.912 1.088l7.028.043m0 0l.043 7.028M7.94 1.131L.869 8.203"></path></svg></span></a><a aria-label="" target="_blank" rel="no-referrer" href="mailto:xyz@abc.com?subject=Eclipse VC - &amp;body=Check this website "><span class="ThemedButton ThemedButton_ThemedButton__Hdkso SocialShare_emailAnchor__2HCYL SocialShare_button__SJnz4 ThemedButton_icon__OZyeS">Share by email<svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 9 9" class="ThemedButton_svg__7_dpk"><path stroke="currentColor" stroke-linecap="square" stroke-width="0.67" d="M.912 1.088l7.028.043m0 0l.043 7.028M7.94 1.131L.869 8.203"></path></svg></span></a></div></div></div><hr class="Separator_Separator__8u4Nb"/></section><section><div class="FreeForm_FreeForm__IeMdK"><div class="FreeForm_content__1PLNx"><div><p><span>Today, the </span><a data-internal-link="true" href="../../team/index.html"><span>Eclipse team</span></a><span> is excited to </span><b>announce the creation and funding of </b><a href="http://nucleusrad.com"><b>Nucleus Radiopharma</b></a><span>. It is a new </span><span>company we’ve built with </span><a href="https://www.mayoclinic.org/"><span>Mayo Clinic</span></a><span> to ensure cancer patients can access potentially life-saving radiopharmaceuticals by developing technologies to modernize the clinical development, manufacturing, and supply chain of these critical therapies.&nbsp;</span></p>
<p><span>We were inspired to start this company for a simple reason: targeted </span><a href="https://www.cancer.gov/news-events/cancer-currents-blog/2020/radiopharmaceuticals-cancer-radiation-therapy#:~:text=Radiopharmaceuticals%20consist%20of%20a%20radioactive,linker%20that%20joins%20the%20two.&amp;text=The%20past%20two%20decades%20have,grow%2C%20divide%2C%20and%20spread."><span>radiopharmaceuticals</span></a><span> are </span><a href="https://www.novartis.com/news/media-releases/novartis-pluvictotm-approved-fda-first-targeted-radioligand-therapy-treatment-progressive-psma-positive-metastatic-castration-resistant-prostate-cancer"><span>providing life changing results</span></a><span>, but are only reaching a fraction of eligible patients due to manufacturing and supply chain issues. These new therapies are showing great promise for patients as they have the ability to precisely target and kill tumors, while sparing healthy cells and with minimal side effects. However, they also have complex raw material streams, specialized manufacturing methods, and short-lived radioactivity, which means they must be produced daily, often in small batches, and usually on a patient-by-patient basis. Patients currently sit on waitlists for these therapies for weeks or months, assuming they have access to a qualified center at all.&nbsp;</span></p>
<p><span>Drawing from Eclipse’s experience creating companies with advanced manufacturing technologies, as well as the deep oncology expertise of Mayo Clinic, Nucleus will partner with the pharmaceutical industry to bring these treatments to the market at a cost, scale, and efficacy that will impact millions of people’s lives. It is clear that we can’t manufacture new therapeutic modalities, such as radiopharmaceuticals, via traditional pharmaceutical manufacturing techniques. These modalities require new infrastructure to unlock their full potential. With the creation of Nucleus, for the first time, a single company will provide the radiopharma industry clinical operations support, full end-to-end manufacturing capabilities, and supply chain fulfillment from clinical trials to commercial deployment.</span></p>
<p><span>These audacious goals cannot be achieved without the world-class team we have assembled. </span><a href="https://www.linkedin.com/in/charlesconroyrph/"><span>Charles Conroy,</span></a><span> one of the world’s leading experts in radiopharmaceuticals and former CEO of ARTMS Inc., is leading Nucleus as CEO. I’m also honored to sit on the Board of Directors with an incredible group of industry experts: </span><a href="https://www.linkedin.com/in/manu007/"><span>Manu Nair,</span></a><span> Chair of Corporate Development at Mayo Clinic; </span><a href="https://www.linkedin.com/in/mary-kate-wold-6008263/"><span>Mary Kate Wold</span></a><span>, </span><span>Chief Executive Officer and President of the Church Pension Group and a former senior executive at Wyeth;</span> <a href="https://www.linkedin.com/in/norman-sharpless-1a898080/"><span>Ned Sharpless</span></a><span>, M.D., former Director of the National Cancer Institute and former Acting Commissioner of the FDA; and </span><a href="https://www.linkedin.com/in/michael-rossi-358066b/"><span>Mike Rossi</span></a><span>, former head of radioligand therapy and imaging at Novartis. The diverse and tremendously successful background of the board represents the collective expertise required to execute on Nucleus’ mission.</span></p>
<p><span>In order to better serve the needs of cancer patients, we must increase the supply of radiopharmaceuticals to give hospitals the ability to expand patient access. By fast tracking the next generation of therapies, Nucleus is bridging the gap between innovation and clinic, enabling these new drugs to be deployed to a much wider portion of the population. The </span><a data-internal-link="true" href="../../team/index.html"><span>Eclipse team</span></a><span> is honored to partner with the Mayo Clinic and the Nucleus teams to provide new hope for cancer patients around the world.</span></p>
<p><i><span>Follow Eclipse on </span></i><a href="https://www.linkedin.com/company/eclipse-ventures-llc/"><i><span>LinkedIn</span></i></a><i><span> and </span></i><a href="https://twitter.com/EclipseVentures"><i><span>Twitter</span></i></a><i><span> for the latest on the Industrial Evolution.</span></i></p>
</div></div></div><div class="PostComponent_wrapper__TWi06"><div class="SocialShare_SocialShare___TeOc"><p class="SocialShare_text___6CJT">Share</p><span class="SocialShare_separator___IJQy"></span><a aria-label="" target="_blank" rel="no-referrer" href="https://eclipse.vc/blog/[postSlug]/"><span class="ThemedButton ThemedButton_ThemedButton__Hdkso SocialShare_button__SJnz4 ThemedButton_icon__OZyeS">Twitter<svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 9 9" class="ThemedButton_svg__7_dpk"><path stroke="currentColor" stroke-linecap="square" stroke-width="0.67" d="M.912 1.088l7.028.043m0 0l.043 7.028M7.94 1.131L.869 8.203"></path></svg></span></a><a aria-label="" target="_blank" rel="no-referrer" href="https://eclipse.vc/blog/[postSlug]/"><span class="ThemedButton ThemedButton_ThemedButton__Hdkso SocialShare_button__SJnz4 ThemedButton_icon__OZyeS">Linkedin<svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 9 9" class="ThemedButton_svg__7_dpk"><path stroke="currentColor" stroke-linecap="square" stroke-width="0.67" d="M.912 1.088l7.028.043m0 0l.043 7.028M7.94 1.131L.869 8.203"></path></svg></span></a><a aria-label="" target="_blank" rel="no-referrer" href="mailto:xyz@abc.com?subject=Eclipse VC - &amp;body=Check this website "><span class="ThemedButton ThemedButton_ThemedButton__Hdkso SocialShare_emailAnchor__2HCYL SocialShare_button__SJnz4 ThemedButton_icon__OZyeS">Share by email<svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 9 9" class="ThemedButton_svg__7_dpk"><path stroke="currentColor" stroke-linecap="square" stroke-width="0.67" d="M.912 1.088l7.028.043m0 0l.043 7.028M7.94 1.131L.869 8.203"></path></svg></span></a></div><div class="Spacer_Spacer__fn2qp" style="--spacer-height:80px" aria-hidden="true"></div><div class="Tags_Tags__SMy5B"><p class="Tags_title__wcq6n">Tags</p><ul><li>Healthcare Infrastructure</li><li>Manufacturing</li><li>Mayo Clinic</li><li>Nucleus</li><li>Portfolio Announcement</li><li>Radiopharmaceuticals</li><li>Supply Chain</li></ul></div><div class="Spacer_Spacer__fn2qp" style="--spacer-height:100px" aria-hidden="true"></div></div></section><section><hr class="Separator_Separator__8u4Nb"/><div class="Spacer_Spacer__fn2qp" style="--spacer-height:100px" aria-hidden="true"></div><h3 class="PostComponent_relatedTitle__QdDO2">Related Articles</h3><div class="Spacer_Spacer__fn2qp" style="--spacer-height:100px" aria-hidden="true"></div><div class=""><div class="PostGrid PostGrid_PostGrid__aoT4H PostGrid_count-1__BSFTM"></div></div></section></main><footer class="Footer_Footer__0JIWi"><div class="Footer_wrapper__fRar6 wrapper"><div class="Footer_footerTop__2eyMt"><div class="Footer_companyName__jwFKL company"><div class="Footer_title__o3sfG">Eclipse</div><div class="Footer_eclipse__MnkOJ"></div></div><div class="Footer_newsletterWrapper__2rF4r"><div class="Newsletter_Newsletter__MweEz Newsletter_light__14hIp"><div class="Newsletter_title__YK3ec title">Get the latest news on the Industrial Evolution</div><form class="Newsletter_form__L5fYj"><div class="Newsletter_email__viMdB"><input type="email" placeholder="your@email.com" class="fadeInFrom"/><button class="Newsletter_circle__9XrEQ Newsletter_submit__29xDO fadeInFrom"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 17 17" class="Newsletter_svg__zfXqx"><path stroke="currentColor" stroke-linecap="square" d="M8.591 1L16 8.5m0 0L8.591 16M16 8.5H1"></path></svg></button><span class="Newsletter_underline__89rlp underline"></span></div></form></div></div></div><div class="Footer_footerMiddle__iqB6C extraLink"><div class="Footer_contactInfo__7IDqF"><a aria-label="address-link" target="_blank" class="Footer_address__pzkdv" href="https://goo.gl/maps/ebvadmpmq7AbN2st8">514 High Street<br />
Palo Alto, CA 94301</a><a aria-label="tel-link" class="Footer_phone__XGRgg" href="tel:650-720-4667">650-720-4667</a><a aria-label="email-link" href="mailto:admin@eclipse.vc"><span class="ThemedButton ThemedButton_ThemedButton__Hdkso ThemedButton_action__Jq_He ThemedButton_light__5VNKJ">admin@eclipse.vc</span></a></div><div class="Footer_menuLinks__t10mp"><ul class="Footer_socialLinks__VDbnR"><li><a aria-label="Twitter-menu" target="_blank" rel="no-referrer" href="https://twitter.com/eclipseventures"><span class="ThemedButton ThemedButton_ThemedButton__Hdkso ThemedButton_action__Jq_He ThemedButton_light__5VNKJ">Twitter</span></a></li><li><a aria-label="Linkedin-menu" target="_blank" rel="no-referrer" href="https://www.linkedin.com/company/eclipse-ventures-llc/"><span class="ThemedButton ThemedButton_ThemedButton__Hdkso ThemedButton_action__Jq_He ThemedButton_light__5VNKJ">Linkedin</span></a></li><li><a aria-label="Crunchbase-menu" target="_blank" rel="no-referrer" href="https://www.crunchbase.com/organization/eclipse-ventures"><span class="ThemedButton ThemedButton_ThemedButton__Hdkso ThemedButton_action__Jq_He ThemedButton_light__5VNKJ">Crunchbase</span></a></li></ul><ul class="Footer_externalLinks__UUA3D"><li><a aria-label="LP Portal-menu" target="_blank" rel="no-referrer" href="https://eclipse.arkpes.com/"><span class="ThemedButton ThemedButton_ThemedButton__Hdkso ThemedButton_icon__OZyeS">LP Portal<svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 9 9" class="ThemedButton_svg__7_dpk"><path stroke="currentColor" stroke-linecap="square" stroke-width="0.67" d="M.912 1.088l7.028.043m0 0l.043 7.028M7.94 1.131L.869 8.203"></path></svg></span></a></li><li><a aria-label="Portfolio Careers-menu" target="_blank" rel="no-referrer" href="https://jobs.eclipse.vc/"><span class="ThemedButton ThemedButton_ThemedButton__Hdkso ThemedButton_icon__OZyeS">Portfolio Careers<svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 9 9" class="ThemedButton_svg__7_dpk"><path stroke="currentColor" stroke-linecap="square" stroke-width="0.67" d="M.912 1.088l7.028.043m0 0l.043 7.028M7.94 1.131L.869 8.203"></path></svg></span></a></li><li><a aria-label="Submit a Business Plan-menu" target="_blank" rel="no-referrer" href="mailto:admin@eclipse.vc"><span class="ThemedButton ThemedButton_ThemedButton__Hdkso ThemedButton_icon__OZyeS">Submit a Business Plan<svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 9 9" class="ThemedButton_svg__7_dpk"><path stroke="currentColor" stroke-linecap="square" stroke-width="0.67" d="M.912 1.088l7.028.043m0 0l.043 7.028M7.94 1.131L.869 8.203"></path></svg></span></a></li></ul></div></div><div class="Footer_footerBottom__iA_rq extraLink"><div class="Footer_left__XgdHt"><div class="Footer_inner__IgH_A"><span>&copy;</span>2024<!-- --> Eclipse</div><button class="Footer_backToTop__it2VF">Back To Top<span class="Footer_circle__P_Fwi"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 25 25" class="Footer_svg__EkLP7"><path stroke="currentColor" stroke-linecap="square" d="M19 11l-6.5 6L6 11"></path></svg></span></button></div><ul class="Footer_links__4bN4O"><li><a aria-label="Privacy policy-menu" href="../../privacy-policy/index.html"><span class="ThemedButton ThemedButton_ThemedButton__Hdkso ThemedButton_action__Jq_He ThemedButton_light__5VNKJ">Privacy policy</span></a></li><li><a aria-label="Terms of service-menu" href="../../terms/index.html"><span class="ThemedButton ThemedButton_ThemedButton__Hdkso ThemedButton_action__Jq_He ThemedButton_light__5VNKJ">Terms of service</span></a></li></ul></div></div></footer><div id="portal"></div></div><script id="__MENUS_DATA__" type="application/json" crossorigin="anonymous">{"acfOptionsFooter":{"footerSettings":{"address":"514 High Street<br />\r\nPalo Alto, CA 94301","newsletterTitle":"Get the latest news on the Industrial Evolution","addressLink":"https://goo.gl/maps/ebvadmpmq7AbN2st8","email":"admin@eclipse.vc","phoneNumber":"650-720-4667","links":[{"url":"/privacy-policy/","label":"Privacy policy"},{"url":"/terms/","label":"Terms of service"}],"externalLinks":[{"fieldGroupName":"external_links","label":"LP Portal","url":"https://eclipse.arkpes.com/"},{"fieldGroupName":"external_links","label":"Portfolio Careers","url":"https://jobs.eclipse.vc/"},{"fieldGroupName":"external_links","label":"Submit a Business Plan","url":"mailto:admin@eclipse.vc"}],"socialMedia":[{"mediaUrl":"https://twitter.com/eclipseventures","mediaLabel":"Twitter"},{"mediaUrl":"https://www.linkedin.com/company/eclipse-ventures-llc/","mediaLabel":"Linkedin"},{"mediaUrl":"https://www.crunchbase.com/organization/eclipse-ventures","mediaLabel":"Crunchbase"}]}},"menuItems":{"nodes":[{"parentId":null,"label":"Our Perspective","path":"/perspective/","childItems":{"nodes":[{"label":"Mission","path":"/perspective/"},{"label":"ECO Report","path":"https://ecoreport.eclipse.vc"}]}},{"parentId":"cG9zdDoxNTgx","label":"Mission","path":"/perspective/","childItems":{"nodes":[]}},{"parentId":"cG9zdDoxNTgx","label":"ECO Report","path":"https://ecoreport.eclipse.vc","childItems":{"nodes":[]}},{"parentId":null,"label":"Our Team","path":"/team/","childItems":{"nodes":[]}},{"parentId":null,"label":"Our Companies","path":"/portfolio/","childItems":{"nodes":[]}},{"parentId":null,"label":"News & Insights","path":"/blog/","childItems":{"nodes":[{"label":"Blog","path":"/blog/"},{"label":"Recent Press","path":"/press/"}]}},{"parentId":"cG9zdDoxMDA4","label":"Blog","path":"/blog/","childItems":{"nodes":[]}},{"parentId":"cG9zdDoxMDA4","label":"Recent Press","path":"/press/","childItems":{"nodes":[]}}]},"allSettings":{"generalSettingsTitle":"Eclipse"}}</script><script id="__NEXT_DATA__" type="application/json">{"props":{"pageProps":{"__CLIENT_CACHE_PROP":"{\"cache\":{\"post_18f38_e5c28\":{\"__typename\":\"Post\",\"id\":\"cG9zdDoxNjYx\",\"date\":\"2022-10-12T15:58:04\",\"title_b28e9_bf21a\":\"A New Era in Radiopharmaceutical Development, Supply Chain, and Manufacturing: Introducing Nucleus Radiopharma\",\"uri\":\"/blog/a-new-era-in-radiopharmaceutical-development-supply-chain-and-manufacturing-introducing-nucleus-radiopharma/\",\"featuredImage\":{\"__typename\":\"NodeWithFeaturedImageToMediaItemConnectionEdge\",\"node\":{\"__typename\":\"MediaItem\",\"id\":\"cG9zdDoyNzk2\",\"sourceUrl_772ce_bf21a\":\"https://i0.wp.com/eclipsevcprod.wpengine.com/wp-content/uploads/2022/10/Nucleus-Announcement-1.jpg?fit=1280%2C876\u0026ssl=1\",\"altText\":\"\",\"mediaDetails\":{\"__typename\":\"MediaDetails\",\"width\":1280,\"height\":876}}},\"content_b28e9_bf21a\":\"\u003cp\u003e\u003cspan style=\\\"font-weight: 400;\\\"\u003eToday, the \u003c/span\u003e\u003ca data-internal-link=\\\"true\\\" href=\\\"https://eclipse.vc/team/\\\"\u003e\u003cspan style=\\\"font-weight: 400;\\\"\u003eEclipse team\u003c/span\u003e\u003c/a\u003e\u003cspan style=\\\"font-weight: 400;\\\"\u003e is excited to \u003c/span\u003e\u003cb\u003eannounce the creation and funding of \u003c/b\u003e\u003ca href=\\\"http://nucleusrad.com\\\"\u003e\u003cb\u003eNucleus Radiopharma\u003c/b\u003e\u003c/a\u003e\u003cspan style=\\\"font-weight: 400;\\\"\u003e. It is a new \u003c/span\u003e\u003cspan style=\\\"font-weight: 400;\\\"\u003ecompany we’ve built with \u003c/span\u003e\u003ca href=\\\"https://www.mayoclinic.org/\\\"\u003e\u003cspan style=\\\"font-weight: 400;\\\"\u003eMayo Clinic\u003c/span\u003e\u003c/a\u003e\u003cspan style=\\\"font-weight: 400;\\\"\u003e to ensure cancer patients can access potentially life-saving radiopharmaceuticals by developing technologies to modernize the clinical development, manufacturing, and supply chain of these critical therapies.\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\\n\u003cp\u003e\u003cspan style=\\\"font-weight: 400;\\\"\u003eWe were inspired to start this company for a simple reason: targeted \u003c/span\u003e\u003ca href=\\\"https://www.cancer.gov/news-events/cancer-currents-blog/2020/radiopharmaceuticals-cancer-radiation-therapy#:~:text=Radiopharmaceuticals%20consist%20of%20a%20radioactive,linker%20that%20joins%20the%20two.\u0026amp;text=The%20past%20two%20decades%20have,grow%2C%20divide%2C%20and%20spread.\\\"\u003e\u003cspan style=\\\"font-weight: 400;\\\"\u003eradiopharmaceuticals\u003c/span\u003e\u003c/a\u003e\u003cspan style=\\\"font-weight: 400;\\\"\u003e are \u003c/span\u003e\u003ca href=\\\"https://www.novartis.com/news/media-releases/novartis-pluvictotm-approved-fda-first-targeted-radioligand-therapy-treatment-progressive-psma-positive-metastatic-castration-resistant-prostate-cancer\\\"\u003e\u003cspan style=\\\"font-weight: 400;\\\"\u003eproviding life changing results\u003c/span\u003e\u003c/a\u003e\u003cspan style=\\\"font-weight: 400;\\\"\u003e, but are only reaching a fraction of eligible patients due to manufacturing and supply chain issues. These new therapies are showing great promise for patients as they have the ability to precisely target and kill tumors, while sparing healthy cells and with minimal side effects. However, they also have complex raw material streams, specialized manufacturing methods, and short-lived radioactivity, which means they must be produced daily, often in small batches, and usually on a patient-by-patient basis. Patients currently sit on waitlists for these therapies for weeks or months, assuming they have access to a qualified center at all.\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\\n\u003cp\u003e\u003cspan style=\\\"font-weight: 400;\\\"\u003eDrawing from Eclipse’s experience creating companies with advanced manufacturing technologies, as well as the deep oncology expertise of Mayo Clinic, Nucleus will partner with the pharmaceutical industry to bring these treatments to the market at a cost, scale, and efficacy that will impact millions of people’s lives. It is clear that we can’t manufacture new therapeutic modalities, such as radiopharmaceuticals, via traditional pharmaceutical manufacturing techniques. These modalities require new infrastructure to unlock their full potential. With the creation of Nucleus, for the first time, a single company will provide the radiopharma industry clinical operations support, full end-to-end manufacturing capabilities, and supply chain fulfillment from clinical trials to commercial deployment.\u003c/span\u003e\u003c/p\u003e\\n\u003cp\u003e\u003cspan style=\\\"font-weight: 400;\\\"\u003eThese audacious goals cannot be achieved without the world-class team we have assembled. \u003c/span\u003e\u003ca href=\\\"https://www.linkedin.com/in/charlesconroyrph/\\\"\u003e\u003cspan style=\\\"font-weight: 400;\\\"\u003eCharles Conroy,\u003c/span\u003e\u003c/a\u003e\u003cspan style=\\\"font-weight: 400;\\\"\u003e one of the world’s leading experts in radiopharmaceuticals and former CEO of ARTMS Inc., is leading Nucleus as CEO. I’m also honored to sit on the Board of Directors with an incredible group of industry experts: \u003c/span\u003e\u003ca href=\\\"https://www.linkedin.com/in/manu007/\\\"\u003e\u003cspan style=\\\"font-weight: 400;\\\"\u003eManu Nair,\u003c/span\u003e\u003c/a\u003e\u003cspan style=\\\"font-weight: 400;\\\"\u003e Chair of Corporate Development at Mayo Clinic; \u003c/span\u003e\u003ca href=\\\"https://www.linkedin.com/in/mary-kate-wold-6008263/\\\"\u003e\u003cspan style=\\\"font-weight: 400;\\\"\u003eMary Kate Wold\u003c/span\u003e\u003c/a\u003e\u003cspan style=\\\"font-weight: 400;\\\"\u003e, \u003c/span\u003e\u003cspan style=\\\"font-weight: 400;\\\"\u003eChief Executive Officer and President of the Church Pension Group and a former senior executive at Wyeth;\u003c/span\u003e \u003ca href=\\\"https://www.linkedin.com/in/norman-sharpless-1a898080/\\\"\u003e\u003cspan style=\\\"font-weight: 400;\\\"\u003eNed Sharpless\u003c/span\u003e\u003c/a\u003e\u003cspan style=\\\"font-weight: 400;\\\"\u003e, M.D., former Director of the National Cancer Institute and former Acting Commissioner of the FDA; and \u003c/span\u003e\u003ca href=\\\"https://www.linkedin.com/in/michael-rossi-358066b/\\\"\u003e\u003cspan style=\\\"font-weight: 400;\\\"\u003eMike Rossi\u003c/span\u003e\u003c/a\u003e\u003cspan style=\\\"font-weight: 400;\\\"\u003e, former head of radioligand therapy and imaging at Novartis. The diverse and tremendously successful background of the board represents the collective expertise required to execute on Nucleus’ mission.\u003c/span\u003e\u003c/p\u003e\\n\u003cp\u003e\u003cspan style=\\\"font-weight: 400;\\\"\u003eIn order to better serve the needs of cancer patients, we must increase the supply of radiopharmaceuticals to give hospitals the ability to expand patient access. By fast tracking the next generation of therapies, Nucleus is bridging the gap between innovation and clinic, enabling these new drugs to be deployed to a much wider portion of the population. The \u003c/span\u003e\u003ca data-internal-link=\\\"true\\\" href=\\\"https://eclipse.vc/team/\\\"\u003e\u003cspan style=\\\"font-weight: 400;\\\"\u003eEclipse team\u003c/span\u003e\u003c/a\u003e\u003cspan style=\\\"font-weight: 400;\\\"\u003e is honored to partner with the Mayo Clinic and the Nucleus teams to provide new hope for cancer patients around the world.\u003c/span\u003e\u003c/p\u003e\\n\u003cp\u003e\u003ci\u003e\u003cspan style=\\\"font-weight: 400;\\\"\u003eFollow Eclipse on \u003c/span\u003e\u003c/i\u003e\u003ca href=\\\"https://www.linkedin.com/company/eclipse-ventures-llc/\\\"\u003e\u003ci\u003e\u003cspan style=\\\"font-weight: 400;\\\"\u003eLinkedIn\u003c/span\u003e\u003c/i\u003e\u003c/a\u003e\u003ci\u003e\u003cspan style=\\\"font-weight: 400;\\\"\u003e and \u003c/span\u003e\u003c/i\u003e\u003ca href=\\\"https://twitter.com/EclipseVentures\\\"\u003e\u003ci\u003e\u003cspan style=\\\"font-weight: 400;\\\"\u003eTwitter\u003c/span\u003e\u003c/i\u003e\u003c/a\u003e\u003ci\u003e\u003cspan style=\\\"font-weight: 400;\\\"\u003e for the latest on the Industrial Evolution.\u003c/span\u003e\u003c/i\u003e\u003c/p\u003e\\n\",\"categories_3cd3e_bf21a\":{\"__typename\":\"PostToCategoryConnection\",\"nodes\":[{\"__typename\":\"Category\",\"id\":\"dGVybToxNjU=\",\"name\":\"News\",\"databaseId\":165,\"slug\":\"news\",\"count\":20}]},\"seo\":{\"__typename\":\"PostTypeSEO\",\"title\":\"A New Era in Radiopharmaceutical Development, Supply Chain, and Manufacturing: Introducing Nucleus Radiopharma - Eclipse\",\"fullHead\":\"\u003c!-- This site is optimized with the Yoast SEO plugin v19.9 - https://yoast.com/wordpress/plugins/seo/ --\u003e\\n\u003clink rel=\\\"canonical\\\" href=\\\"https://eclipse.vc/blog/a-new-era-in-radiopharmaceutical-development-supply-chain-and-manufacturing-introducing-nucleus-radiopharma/\\\" /\u003e\\n\u003cmeta property=\\\"og:locale\\\" content=\\\"en_US\\\" /\u003e\\n\u003cmeta property=\\\"og:type\\\" content=\\\"article\\\" /\u003e\\n\u003cmeta property=\\\"og:title\\\" content=\\\"A New Era in Radiopharmaceutical Development, Supply Chain, and Manufacturing: Introducing Nucleus Radiopharma - Eclipse\\\" /\u003e\\n\u003cmeta property=\\\"og:description\\\" content=\\\"The Eclipse team is excited to announce the creation and funding of Nucleus Radiopharma in partnership with Mayo Clinic\\\" /\u003e\\n\u003cmeta property=\\\"og:url\\\" content=\\\"https://eclipse.vc/blog/a-new-era-in-radiopharmaceutical-development-supply-chain-and-manufacturing-introducing-nucleus-radiopharma/\\\" /\u003e\\n\u003cmeta property=\\\"og:site_name\\\" content=\\\"Eclipse\\\" /\u003e\\n\u003cmeta property=\\\"article:published_time\\\" content=\\\"2022-10-12T15:58:04+00:00\\\" /\u003e\\n\u003cmeta property=\\\"article:modified_time\\\" content=\\\"2022-11-03T19:48:39+00:00\\\" /\u003e\\n\u003cmeta property=\\\"og:image\\\" content=\\\"https://eclipsevcprod.wpengine.com/wp-content/uploads/2022/10/Nucleus-Announcement-1.jpg\\\" /\u003e\\n\\t\u003cmeta property=\\\"og:image:width\\\" content=\\\"1280\\\" /\u003e\\n\\t\u003cmeta property=\\\"og:image:height\\\" content=\\\"876\\\" /\u003e\\n\\t\u003cmeta property=\\\"og:image:type\\\" content=\\\"image/jpeg\\\" /\u003e\\n\u003cmeta name=\\\"author\\\" content=\\\"Justin Butler\\\" /\u003e\\n\u003cmeta name=\\\"twitter:card\\\" content=\\\"summary_large_image\\\" /\u003e\\n\u003cmeta name=\\\"twitter:creator\\\" content=\\\"@eclipseventures\\\" /\u003e\\n\u003cmeta name=\\\"twitter:site\\\" content=\\\"@eclipseventures\\\" /\u003e\\n\u003cmeta name=\\\"twitter:label1\\\" content=\\\"Written by\\\" /\u003e\\n\\t\u003cmeta name=\\\"twitter:data1\\\" content=\\\"Justin Butler\\\" /\u003e\\n\\t\u003cmeta name=\\\"twitter:label2\\\" content=\\\"Est. reading time\\\" /\u003e\\n\\t\u003cmeta name=\\\"twitter:data2\\\" content=\\\"3 minutes\\\" /\u003e\\n\u003cscript type=\\\"application/ld+json\\\" class=\\\"yoast-schema-graph\\\"\u003e{\\\"@context\\\":\\\"https://schema.org\\\",\\\"@graph\\\":[{\\\"@type\\\":\\\"WebPage\\\",\\\"@id\\\":\\\"https://eclipse.vc/blog/a-new-era-in-radiopharmaceutical-development-supply-chain-and-manufacturing-introducing-nucleus-radiopharma/\\\",\\\"url\\\":\\\"https://eclipse.vc/blog/a-new-era-in-radiopharmaceutical-development-supply-chain-and-manufacturing-introducing-nucleus-radiopharma/\\\",\\\"name\\\":\\\"A New Era in Radiopharmaceutical Development, Supply Chain, and Manufacturing: Introducing Nucleus Radiopharma - Eclipse\\\",\\\"isPartOf\\\":{\\\"@id\\\":\\\"https://eclipsevcprod.wpengine.com/#website\\\"},\\\"primaryImageOfPage\\\":{\\\"@id\\\":\\\"https://eclipse.vc/blog/a-new-era-in-radiopharmaceutical-development-supply-chain-and-manufacturing-introducing-nucleus-radiopharma/#primaryimage\\\"},\\\"image\\\":{\\\"@id\\\":\\\"https://eclipse.vc/blog/a-new-era-in-radiopharmaceutical-development-supply-chain-and-manufacturing-introducing-nucleus-radiopharma/#primaryimage\\\"},\\\"thumbnailUrl\\\":\\\"https://i0.wp.com/eclipsevcprod.wpengine.com/wp-content/uploads/2022/10/Nucleus-Announcement-1.jpg?fit=1280%2C876\u0026ssl=1\\\",\\\"datePublished\\\":\\\"2022-10-12T15:58:04+00:00\\\",\\\"dateModified\\\":\\\"2022-11-03T19:48:39+00:00\\\",\\\"author\\\":{\\\"@id\\\":\\\"https://eclipsevcprod.wpengine.com/#/schema/person/a11b6fbff0284496e1bbe2056e0bf6d5\\\"},\\\"breadcrumb\\\":{\\\"@id\\\":\\\"https://eclipse.vc/blog/a-new-era-in-radiopharmaceutical-development-supply-chain-and-manufacturing-introducing-nucleus-radiopharma/#breadcrumb\\\"},\\\"inLanguage\\\":\\\"en-US\\\",\\\"potentialAction\\\":[{\\\"@type\\\":\\\"ReadAction\\\",\\\"target\\\":[\\\"https://eclipse.vc/blog/a-new-era-in-radiopharmaceutical-development-supply-chain-and-manufacturing-introducing-nucleus-radiopharma/\\\"]}]},{\\\"@type\\\":\\\"ImageObject\\\",\\\"inLanguage\\\":\\\"en-US\\\",\\\"@id\\\":\\\"https://eclipse.vc/blog/a-new-era-in-radiopharmaceutical-development-supply-chain-and-manufacturing-introducing-nucleus-radiopharma/#primaryimage\\\",\\\"url\\\":\\\"https://i0.wp.com/eclipsevcprod.wpengine.com/wp-content/uploads/2022/10/Nucleus-Announcement-1.jpg?fit=1280%2C876\u0026ssl=1\\\",\\\"contentUrl\\\":\\\"https://i0.wp.com/eclipsevcprod.wpengine.com/wp-content/uploads/2022/10/Nucleus-Announcement-1.jpg?fit=1280%2C876\u0026ssl=1\\\",\\\"width\\\":1280,\\\"height\\\":876},{\\\"@type\\\":\\\"BreadcrumbList\\\",\\\"@id\\\":\\\"https://eclipse.vc/blog/a-new-era-in-radiopharmaceutical-development-supply-chain-and-manufacturing-introducing-nucleus-radiopharma/#breadcrumb\\\",\\\"itemListElement\\\":[{\\\"@type\\\":\\\"ListItem\\\",\\\"position\\\":1,\\\"name\\\":\\\"Home\\\",\\\"item\\\":\\\"https://eclipse.vc/\\\"},{\\\"@type\\\":\\\"ListItem\\\",\\\"position\\\":2,\\\"name\\\":\\\"A New Era in Radiopharmaceutical Development, Supply Chain, and Manufacturing: Introducing Nucleus Radiopharma\\\"}]},{\\\"@type\\\":\\\"WebSite\\\",\\\"@id\\\":\\\"https://eclipsevcprod.wpengine.com/#website\\\",\\\"url\\\":\\\"https://eclipsevcprod.wpengine.com/\\\",\\\"name\\\":\\\"Eclipse\\\",\\\"description\\\":\\\"Just another WordPress site\\\",\\\"potentialAction\\\":[{\\\"@type\\\":\\\"SearchAction\\\",\\\"target\\\":{\\\"@type\\\":\\\"EntryPoint\\\",\\\"urlTemplate\\\":\\\"https://eclipsevcprod.wpengine.com/?s={search_term_string}\\\"},\\\"query-input\\\":\\\"required name=search_term_string\\\"}],\\\"inLanguage\\\":\\\"en-US\\\"},{\\\"@type\\\":\\\"Person\\\",\\\"@id\\\":\\\"https://eclipsevcprod.wpengine.com/#/schema/person/a11b6fbff0284496e1bbe2056e0bf6d5\\\",\\\"name\\\":\\\"Justin Butler\\\",\\\"image\\\":{\\\"@type\\\":\\\"ImageObject\\\",\\\"inLanguage\\\":\\\"en-US\\\",\\\"@id\\\":\\\"https://eclipsevcprod.wpengine.com/#/schema/person/image/\\\",\\\"url\\\":\\\"https://secure.gravatar.com/avatar/7bd4dbca88ac7a9e2a5851061b2630fa?s=96\u0026d=mm\u0026r=g\\\",\\\"contentUrl\\\":\\\"https://secure.gravatar.com/avatar/7bd4dbca88ac7a9e2a5851061b2630fa?s=96\u0026d=mm\u0026r=g\\\",\\\"caption\\\":\\\"Justin Butler\\\"},\\\"url\\\":\\\"https://eclipsevcprod.wpengine.com/blog/author/justin-butler/\\\"}]}\u003c/script\u003e\\n\u003c!-- / Yoast SEO plugin. --\u003e\"},\"blocksJSON\":\"[{\\\"innerBlocks\\\":[],\\\"name\\\":\\\"core\\\\/freeform\\\",\\\"postId\\\":1661,\\\"blockType\\\":{\\\"name\\\":\\\"core\\\\/freeform\\\",\\\"keywords\\\":[],\\\"attributes\\\":{\\\"content\\\":{\\\"type\\\":\\\"string\\\",\\\"source\\\":\\\"raw\\\"},\\\"lock\\\":{\\\"type\\\":\\\"object\\\"},\\\"metadata\\\":{\\\"type\\\":\\\"object\\\"}},\\\"providesContext\\\":[],\\\"usesContext\\\":[],\\\"selectors\\\":[],\\\"supports\\\":{\\\"className\\\":false,\\\"customClassName\\\":false,\\\"reusable\\\":false},\\\"styles\\\":[],\\\"variations\\\":[],\\\"blockHooks\\\":[],\\\"apiVersion\\\":3,\\\"title\\\":\\\"Classic\\\",\\\"description\\\":\\\"Use the classic WordPress editor.\\\",\\\"category\\\":\\\"text\\\"},\\\"originalContent\\\":\\\"\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003eToday, the \u003c\\\\/span\u003e\u003ca data-internal-link=\\\\\\\"true\\\\\\\" href=\\\\\\\"https:\\\\/\\\\/eclipse.vc\\\\/team\\\\/\\\\\\\"\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003eEclipse team\u003c\\\\/span\u003e\u003c\\\\/a\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003e is excited to \u003c\\\\/span\u003e\u003cb\u003eannounce the creation and funding of \u003c\\\\/b\u003e\u003ca href=\\\\\\\"http:\\\\/\\\\/nucleusrad.com\\\\\\\"\u003e\u003cb\u003eNucleus Radiopharma\u003c\\\\/b\u003e\u003c\\\\/a\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003e. It is a new \u003c\\\\/span\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003ecompany we\\\\u2019ve built with \u003c\\\\/span\u003e\u003ca href=\\\\\\\"https:\\\\/\\\\/www.mayoclinic.org\\\\/\\\\\\\"\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003eMayo Clinic\u003c\\\\/span\u003e\u003c\\\\/a\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003e to ensure cancer patients can access potentially life-saving radiopharmaceuticals by developing technologies to modernize the clinical development, manufacturing, and supply chain of these critical therapies.\u0026nbsp;\u003c\\\\/span\u003e\\\\n\\\\n\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003eWe were inspired to start this company for a simple reason: targeted \u003c\\\\/span\u003e\u003ca href=\\\\\\\"https:\\\\/\\\\/www.cancer.gov\\\\/news-events\\\\/cancer-currents-blog\\\\/2020\\\\/radiopharmaceuticals-cancer-radiation-therapy#:~:text=Radiopharmaceuticals%20consist%20of%20a%20radioactive,linker%20that%20joins%20the%20two.\u0026amp;text=The%20past%20two%20decades%20have,grow%2C%20divide%2C%20and%20spread.\\\\\\\"\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003eradiopharmaceuticals\u003c\\\\/span\u003e\u003c\\\\/a\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003e are \u003c\\\\/span\u003e\u003ca href=\\\\\\\"https:\\\\/\\\\/www.novartis.com\\\\/news\\\\/media-releases\\\\/novartis-pluvictotm-approved-fda-first-targeted-radioligand-therapy-treatment-progressive-psma-positive-metastatic-castration-resistant-prostate-cancer\\\\\\\"\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003eproviding life changing results\u003c\\\\/span\u003e\u003c\\\\/a\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003e, but are only reaching a fraction of eligible patients due to manufacturing and supply chain issues. These new therapies are showing great promise for patients as they have the ability to precisely target and kill tumors, while sparing healthy cells and with minimal side effects. However, they also have complex raw material streams, specialized manufacturing methods, and short-lived radioactivity, which means they must be produced daily, often in small batches, and usually on a patient-by-patient basis. Patients currently sit on waitlists for these therapies for weeks or months, assuming they have access to a qualified center at all.\u0026nbsp;\u003c\\\\/span\u003e\\\\n\\\\n\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003eDrawing from Eclipse\\\\u2019s experience creating companies with advanced manufacturing technologies, as well as the deep oncology expertise of Mayo Clinic, Nucleus will partner with the pharmaceutical industry to bring these treatments to the market at a cost, scale, and efficacy that will impact millions of people\\\\u2019s lives. It is clear that we can\\\\u2019t manufacture new therapeutic modalities, such as radiopharmaceuticals, via traditional pharmaceutical manufacturing techniques. These modalities require new infrastructure to unlock their full potential. With the creation of Nucleus, for the first time, a single company will provide the radiopharma industry clinical operations support, full end-to-end manufacturing capabilities, and supply chain fulfillment from clinical trials to commercial deployment.\u003c\\\\/span\u003e\\\\n\\\\n\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003eThese audacious goals cannot be achieved without the world-class team we have assembled. \u003c\\\\/span\u003e\u003ca href=\\\\\\\"https:\\\\/\\\\/www.linkedin.com\\\\/in\\\\/charlesconroyrph\\\\/\\\\\\\"\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003eCharles Conroy,\u003c\\\\/span\u003e\u003c\\\\/a\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003e one of the world\\\\u2019s leading experts in radiopharmaceuticals and former CEO of ARTMS Inc., is leading Nucleus as CEO. I\\\\u2019m also honored to sit on the Board of Directors with an incredible group of industry experts: \u003c\\\\/span\u003e\u003ca href=\\\\\\\"https:\\\\/\\\\/www.linkedin.com\\\\/in\\\\/manu007\\\\/\\\\\\\"\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003eManu Nair,\u003c\\\\/span\u003e\u003c\\\\/a\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003e Chair of Corporate Development at Mayo Clinic; \u003c\\\\/span\u003e\u003ca href=\\\\\\\"https:\\\\/\\\\/www.linkedin.com\\\\/in\\\\/mary-kate-wold-6008263\\\\/\\\\\\\"\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003eMary Kate Wold\u003c\\\\/span\u003e\u003c\\\\/a\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003e, \u003c\\\\/span\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003eChief Executive Officer and President of the Church Pension Group and a former senior executive at Wyeth;\u003c\\\\/span\u003e \u003ca href=\\\\\\\"https:\\\\/\\\\/www.linkedin.com\\\\/in\\\\/norman-sharpless-1a898080\\\\/\\\\\\\"\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003eNed Sharpless\u003c\\\\/span\u003e\u003c\\\\/a\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003e, M.D., former Director of the National Cancer Institute and former Acting Commissioner of the FDA; and \u003c\\\\/span\u003e\u003ca href=\\\\\\\"https:\\\\/\\\\/www.linkedin.com\\\\/in\\\\/michael-rossi-358066b\\\\/\\\\\\\"\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003eMike Rossi\u003c\\\\/span\u003e\u003c\\\\/a\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003e, former head of radioligand therapy and imaging at Novartis. The diverse and tremendously successful background of the board represents the collective expertise required to execute on Nucleus\\\\u2019 mission.\u003c\\\\/span\u003e\\\\n\\\\n\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003eIn order to better serve the needs of cancer patients, we must increase the supply of radiopharmaceuticals to give hospitals the ability to expand patient access. By fast tracking the next generation of therapies, Nucleus is bridging the gap between innovation and clinic, enabling these new drugs to be deployed to a much wider portion of the population. The \u003c\\\\/span\u003e\u003ca data-internal-link=\\\\\\\"true\\\\\\\" href=\\\\\\\"https:\\\\/\\\\/eclipse.vc\\\\/team\\\\/\\\\\\\"\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003eEclipse team\u003c\\\\/span\u003e\u003c\\\\/a\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003e is honored to partner with the Mayo Clinic and the Nucleus teams to provide new hope for cancer patients around the world.\u003c\\\\/span\u003e\\\\n\\\\n\u003ci\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003eFollow Eclipse on \u003c\\\\/span\u003e\u003c\\\\/i\u003e\u003ca href=\\\\\\\"https:\\\\/\\\\/www.linkedin.com\\\\/company\\\\/eclipse-ventures-llc\\\\/\\\\\\\"\u003e\u003ci\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003eLinkedIn\u003c\\\\/span\u003e\u003c\\\\/i\u003e\u003c\\\\/a\u003e\u003ci\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003e and \u003c\\\\/span\u003e\u003c\\\\/i\u003e\u003ca href=\\\\\\\"https:\\\\/\\\\/twitter.com\\\\/EclipseVentures\\\\\\\"\u003e\u003ci\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003eTwitter\u003c\\\\/span\u003e\u003c\\\\/i\u003e\u003c\\\\/a\u003e\u003ci\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003e for the latest on the Industrial Evolution.\u003c\\\\/span\u003e\u003c\\\\/i\u003e\\\",\\\"saveContent\\\":\\\"\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003eToday, the \u003c\\\\/span\u003e\u003ca data-internal-link=\\\\\\\"true\\\\\\\" href=\\\\\\\"https:\\\\/\\\\/eclipse.vc\\\\/team\\\\/\\\\\\\"\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003eEclipse team\u003c\\\\/span\u003e\u003c\\\\/a\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003e is excited to \u003c\\\\/span\u003e\u003cb\u003eannounce the creation and funding of \u003c\\\\/b\u003e\u003ca href=\\\\\\\"http:\\\\/\\\\/nucleusrad.com\\\\\\\"\u003e\u003cb\u003eNucleus Radiopharma\u003c\\\\/b\u003e\u003c\\\\/a\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003e. It is a new \u003c\\\\/span\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003ecompany we\\\\u2019ve built with \u003c\\\\/span\u003e\u003ca href=\\\\\\\"https:\\\\/\\\\/www.mayoclinic.org\\\\/\\\\\\\"\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003eMayo Clinic\u003c\\\\/span\u003e\u003c\\\\/a\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003e to ensure cancer patients can access potentially life-saving radiopharmaceuticals by developing technologies to modernize the clinical development, manufacturing, and supply chain of these critical therapies.\u0026nbsp;\u003c\\\\/span\u003e\\\\n\\\\n\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003eWe were inspired to start this company for a simple reason: targeted \u003c\\\\/span\u003e\u003ca href=\\\\\\\"https:\\\\/\\\\/www.cancer.gov\\\\/news-events\\\\/cancer-currents-blog\\\\/2020\\\\/radiopharmaceuticals-cancer-radiation-therapy#:~:text=Radiopharmaceuticals%20consist%20of%20a%20radioactive,linker%20that%20joins%20the%20two.\u0026amp;text=The%20past%20two%20decades%20have,grow%2C%20divide%2C%20and%20spread.\\\\\\\"\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003eradiopharmaceuticals\u003c\\\\/span\u003e\u003c\\\\/a\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003e are \u003c\\\\/span\u003e\u003ca href=\\\\\\\"https:\\\\/\\\\/www.novartis.com\\\\/news\\\\/media-releases\\\\/novartis-pluvictotm-approved-fda-first-targeted-radioligand-therapy-treatment-progressive-psma-positive-metastatic-castration-resistant-prostate-cancer\\\\\\\"\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003eproviding life changing results\u003c\\\\/span\u003e\u003c\\\\/a\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003e, but are only reaching a fraction of eligible patients due to manufacturing and supply chain issues. These new therapies are showing great promise for patients as they have the ability to precisely target and kill tumors, while sparing healthy cells and with minimal side effects. However, they also have complex raw material streams, specialized manufacturing methods, and short-lived radioactivity, which means they must be produced daily, often in small batches, and usually on a patient-by-patient basis. Patients currently sit on waitlists for these therapies for weeks or months, assuming they have access to a qualified center at all.\u0026nbsp;\u003c\\\\/span\u003e\\\\n\\\\n\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003eDrawing from Eclipse\\\\u2019s experience creating companies with advanced manufacturing technologies, as well as the deep oncology expertise of Mayo Clinic, Nucleus will partner with the pharmaceutical industry to bring these treatments to the market at a cost, scale, and efficacy that will impact millions of people\\\\u2019s lives. It is clear that we can\\\\u2019t manufacture new therapeutic modalities, such as radiopharmaceuticals, via traditional pharmaceutical manufacturing techniques. These modalities require new infrastructure to unlock their full potential. With the creation of Nucleus, for the first time, a single company will provide the radiopharma industry clinical operations support, full end-to-end manufacturing capabilities, and supply chain fulfillment from clinical trials to commercial deployment.\u003c\\\\/span\u003e\\\\n\\\\n\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003eThese audacious goals cannot be achieved without the world-class team we have assembled. \u003c\\\\/span\u003e\u003ca href=\\\\\\\"https:\\\\/\\\\/www.linkedin.com\\\\/in\\\\/charlesconroyrph\\\\/\\\\\\\"\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003eCharles Conroy,\u003c\\\\/span\u003e\u003c\\\\/a\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003e one of the world\\\\u2019s leading experts in radiopharmaceuticals and former CEO of ARTMS Inc., is leading Nucleus as CEO. I\\\\u2019m also honored to sit on the Board of Directors with an incredible group of industry experts: \u003c\\\\/span\u003e\u003ca href=\\\\\\\"https:\\\\/\\\\/www.linkedin.com\\\\/in\\\\/manu007\\\\/\\\\\\\"\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003eManu Nair,\u003c\\\\/span\u003e\u003c\\\\/a\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003e Chair of Corporate Development at Mayo Clinic; \u003c\\\\/span\u003e\u003ca href=\\\\\\\"https:\\\\/\\\\/www.linkedin.com\\\\/in\\\\/mary-kate-wold-6008263\\\\/\\\\\\\"\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003eMary Kate Wold\u003c\\\\/span\u003e\u003c\\\\/a\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003e, \u003c\\\\/span\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003eChief Executive Officer and President of the Church Pension Group and a former senior executive at Wyeth;\u003c\\\\/span\u003e \u003ca href=\\\\\\\"https:\\\\/\\\\/www.linkedin.com\\\\/in\\\\/norman-sharpless-1a898080\\\\/\\\\\\\"\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003eNed Sharpless\u003c\\\\/span\u003e\u003c\\\\/a\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003e, M.D., former Director of the National Cancer Institute and former Acting Commissioner of the FDA; and \u003c\\\\/span\u003e\u003ca href=\\\\\\\"https:\\\\/\\\\/www.linkedin.com\\\\/in\\\\/michael-rossi-358066b\\\\/\\\\\\\"\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003eMike Rossi\u003c\\\\/span\u003e\u003c\\\\/a\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003e, former head of radioligand therapy and imaging at Novartis. The diverse and tremendously successful background of the board represents the collective expertise required to execute on Nucleus\\\\u2019 mission.\u003c\\\\/span\u003e\\\\n\\\\n\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003eIn order to better serve the needs of cancer patients, we must increase the supply of radiopharmaceuticals to give hospitals the ability to expand patient access. By fast tracking the next generation of therapies, Nucleus is bridging the gap between innovation and clinic, enabling these new drugs to be deployed to a much wider portion of the population. The \u003c\\\\/span\u003e\u003ca data-internal-link=\\\\\\\"true\\\\\\\" href=\\\\\\\"https:\\\\/\\\\/eclipse.vc\\\\/team\\\\/\\\\\\\"\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003eEclipse team\u003c\\\\/span\u003e\u003c\\\\/a\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003e is honored to partner with the Mayo Clinic and the Nucleus teams to provide new hope for cancer patients around the world.\u003c\\\\/span\u003e\\\\n\\\\n\u003ci\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003eFollow Eclipse on \u003c\\\\/span\u003e\u003c\\\\/i\u003e\u003ca href=\\\\\\\"https:\\\\/\\\\/www.linkedin.com\\\\/company\\\\/eclipse-ventures-llc\\\\/\\\\\\\"\u003e\u003ci\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003eLinkedIn\u003c\\\\/span\u003e\u003c\\\\/i\u003e\u003c\\\\/a\u003e\u003ci\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003e and \u003c\\\\/span\u003e\u003c\\\\/i\u003e\u003ca href=\\\\\\\"https:\\\\/\\\\/twitter.com\\\\/EclipseVentures\\\\\\\"\u003e\u003ci\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003eTwitter\u003c\\\\/span\u003e\u003c\\\\/i\u003e\u003c\\\\/a\u003e\u003ci\u003e\u003cspan style=\\\\\\\"font-weight: 400;\\\\\\\"\u003e for the latest on the Industrial Evolution.\u003c\\\\/span\u003e\u003c\\\\/i\u003e\\\",\\\"order\\\":0,\\\"get_parent\\\":{},\\\"attributes\\\":[],\\\"attributesType\\\":{\\\"content\\\":{\\\"type\\\":\\\"string\\\",\\\"source\\\":\\\"raw\\\"},\\\"lock\\\":{\\\"type\\\":\\\"object\\\"},\\\"metadata\\\":{\\\"type\\\":\\\"object\\\"}},\\\"dynamicContent\\\":null}]\",\"author\":{\"__typename\":\"NodeWithAuthorToUserConnectionEdge\",\"node\":{\"__typename\":\"User\",\"id\":\"dXNlcjo3Mw==\",\"name\":\"Justin Butler\"}},\"link\":\"https://eclipsevcprod.wpengine.com/blog/a-new-era-in-radiopharmaceutical-development-supply-chain-and-manufacturing-introducing-nucleus-radiopharma/\",\"tags_67cce_bf21a\":{\"__typename\":\"PostToTagConnection\",\"nodes\":[{\"__typename\":\"Tag\",\"id\":\"dGVybToyMjM=\",\"name\":\"Healthcare Infrastructure\"},{\"__typename\":\"Tag\",\"id\":\"dGVybTozNA==\",\"name\":\"Manufacturing\"},{\"__typename\":\"Tag\",\"id\":\"dGVybToyMTg=\",\"name\":\"Mayo Clinic\"},{\"__typename\":\"Tag\",\"id\":\"dGVybToyMTk=\",\"name\":\"Nucleus\"},{\"__typename\":\"Tag\",\"id\":\"dGVybToxNzg=\",\"name\":\"Portfolio Announcement\"},{\"__typename\":\"Tag\",\"id\":\"dGVybToyMjA=\",\"name\":\"Radiopharmaceuticals\"},{\"__typename\":\"Tag\",\"id\":\"dGVybToyNw==\",\"name\":\"Supply Chain\"}]},\"excerpt_b28e9_bf21a\":\"\u003cp\u003eThe Eclipse team is excited to announce the creation and funding of Nucleus Radiopharma in partnership with Mayo Clinic\u003c/p\u003e\\n\"},\"posts_f30bc_1ccee\":{\"__typename\":\"RootQueryToPostConnection\",\"nodes\":[]}}}","__AUTH_CLIENT_CACHE_PROP":"{}"},"__N_SSG":true},"page":"/blog/[postSlug]","query":{"postSlug":"a-new-era-in-radiopharmaceutical-development-supply-chain-and-manufacturing-introducing-nucleus-radiopharma"},"buildId":"PXZ38zmr2SXTuXgWIih-y","isFallback":false,"gsp":true,"scriptLoader":[{"id":"gtm-script","strategy":"afterInteractive","dangerouslySetInnerHTML":{"__html":"(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':\nnew Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],\nj=d.createElement(s),dl=l!='dataLayer'?'\u0026l='+l:'';j.async=true;j.src=\n'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);\n})(window,document,'script','dataLayer','GTM-KVCPZSV');"}}]}</script></body></html>